| Methods |
Design:
randomized, placebo‐ controlled, double blind
parallel groups
8 weeks |
| Participants |
Country: U.S.A.
n=20 (20 completers) probable AD NINCDS/ADRDA, mild‐moderate dementia (MMSE: 10‐29), Aged 80 (SD 7, 61‐90 yrs). Exclusion criteria: medical, neurological or psychiatric disease. Psychoactive medication, cholinesterase inhibitors or HRT use last for the 2 months. Mixed menopause (all underwent pap smears) |
| Interventions |
1. E2 (17‐beta transdermal 0.10 mg
2. Placebo |
| Outcomes |
General (MMSE, BIMC)
Memory: (BSRT, Paragraph recall, Rey Osterich Visual memory test, Visual Paired Associates, Oculomotor Delayed response), Boston Namin Test (semantic)
Speed (Stroop, TMT), Treisman Visual Search Other: CIBIC, IADL, BPRS, PSMS |
| Notes |
HRT>placebo: attention: Stroop, memory: BSRT, Rey Visual Memory, BNT)
Adverse events: breast tenderness (2 ERT), skin irritation patch (3 on ERT). No bleeding or spotting, no deep vein thrombosis, pulmonary embolism |
